|
ApoImmune, Inc. Awarded NIH Grant for Universal Cancer Vaccine
September 5, 2007 (Louisville, KY) - ApoImmune, Inc. today announced that it has been selected to receive a Phase I Small Business Technology Transfer (STTR) grant of $328,300 for developing a universal cancer vaccine based on the Company's novel ApoVax104 platform technology. The grant was awarded by the National Cancer Institute within the National Institutes of Health (NIH), and is the seventh NIH SBIR/STTR Phase I grant received by the company.
Funding from this award will be used for preclinical work to develop a universal cancer vaccine. The vaccine uses ApoImmune's ApoVax104 technology platform in conjunction with a tumor associated antigen, or tumor marker, that is found in most tumor cell types but is absent in normal non-malignant cells making it a "marker" to identify tumor cells.
ApoImmune President and CEO Steven Downey said in a statement that the company will use these funds for preclinical studies testing the universal cancer vaccine in a lung cancer model. "We are now in a position to expand our cancer vaccine and confirm it's efficacy in a second mouse cancer model" he stated. The Company has already demonstrated therapeutic efficacy of the ApoVax104 vaccine in a cervical cancer model in mice.
About ApoImmune, Inc.
ApoImmune Inc. is a Louisville, Kentucky-based biotechnology company developing novel immunotherapies, which are treatments based on the concept of regulating the immune system to fight disease. The Company's lead immunotherapy is based on the ProtEx technology's ability to teach the immune system to recognize foreign pathogens as harmful and specifically target those harmful cells for destruction. ApoImmune is also developing ProtEx to suppress the immune system in certain cases, which improves current organ and tissue transplant therapies by protecting the transplant from being attacked by the recipient's immune system when transplanted into the body. An added benefit of the ProtEx immune system suppression technology is that it also reduces the need for powerful immunosuppressive drugs with highly toxic effects that are required after transplantation.
For more information, visit www.apoimmune.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
back to Latest News
|
|
|
